Zoetis (ZTS) Misses Q3 EPS by 4c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Bloom Energy shares fall on Oracle project halt
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Zoetis Inc. (ZTS) PT Lowered to $170 at Stifel, Keeps Buy as They See an Opportunity
November 3, 2022 1:54 PM EDTStifel analyst Jonathan Block lowered the price target on Zoetis Inc. (NYSE: ZTS) to $170.00 (from $225.00) while maintaining a Buy rating. The analyst sees an opportunity despite the capitulation.
The analyst commented, "The 3Q22 straight-forward shortfalls were previously detailed in our quick note... More
Cantor Fitzgerald Remains Positive in Zoetis Inc. (ZTS) Growth Prospects Despite Marco Headwinds
November 3, 2022 11:42 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $250.00 price target on Zoetis Inc. (NYSE: ZTS) following today's miss. The analyst is still confident in the growth prospects despite the macro headwinds.
The analyst commented, "Post a 3Q22 sales and EPS miss... More
